4 Analysts Have This to Say About Xenon Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Xenon Pharmaceuticals (NASDAQ:XENE) has received four somewhat bullish analyst ratings in the last quarter, with no bearish or indifferent ratings. The average 12-month price target among these analysts is $54.00, with a high of $63.00 and a low of $46.00. This target represents a 10.2% increase from the previous month. Analyst ratings are based on financial analysis and are intended to guide investors on stock performance.
December 08, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xenon Pharmaceuticals has been rated somewhat bullish by four analysts, with an average price target of $54, indicating a positive sentiment among analysts.
The unanimous somewhat bullish ratings from analysts suggest a positive outlook for XENE, which could lead to increased investor confidence and a potential short-term rise in the stock price. The increase in the average price target over the past month further supports this positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100